4.5 Article

5′ and 3′ untranslated regions contribute to the differential expression of specific HLA-A alleles

Journal

EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 45, Issue 12, Pages 3454-3463

Publisher

WILEY
DOI: 10.1002/eji.201545927

Keywords

Allele; Expression; HLA; Hematopoietic stem cell transplantation; Polymorphism

Categories

Funding

  1. IRGHET foundation (International Research Group on Unrelated Hematopoietic Stem Cell Transplantation)

Ask authors/readers for more resources

In hematopoietic stem cell transplantation (HSCT), when no HLA full-matched donor is available, alternative donors could include one HLA-mismatched donor. Recently, the low expressed HLA-C alleles have been identified as permissive mismatches for the best donor choice. Concerning HLA-A, the degree of variability of expression is poorly understood. Here, we evaluated HLA-A expression in healthy individuals carrying HLA-A*02 allele in different genotypes using flow cytometry and allele-specific quantitative RTPCR. While an interindividual variability of HLA-A*02 cell surface expression, not due to the allele associated, was observed, no difference of the mRNA expression level was shown, suggesting the involvement of the posttranscriptional regulation. The results of qRT-PCR analyses exhibit a differential expression of HLA-A alleles with HLA-A*02 as the strongest expressed allele independently of the second allele. The associated non-HLA-A*02 alleles were differentially expressed, particularly the HLA-A*31 and HLA-A*33 alleles (strong expression) and the HLA-A*29 (low expression). The presence of specific polymorphisms in the 5' and 3' untranslated regions of the HLA-A*31 and HLA-A*33 alleles could contribute to this high level of expression. As previously described for HLA-C, low-expressed HLA-A alleles, such as HLA-A*29, could be considered as a permissive mismatch, although this needs to be confirmed by clinical studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients

Chantal Reina-Ortiz, Michael Constantinides, Alexis Fayd-Herbe-de-Maudave, Jessy Presumey, Javier Hernandez, Guillaume Cartron, Rosana Diez, Isabel Izquierdo, Gemma Azaceta, Luis Palomera, Isabel Marzo, Javier Naval, Alberto Anel, Martin Villalba, David Giraldosa

Summary: The study evaluated the potential of expanded NK cells from two sources combined with mAbs to target primary multiple myeloma cells. Results indicate that umbilical cord blood eNKs are highly cytotoxic against MM cells, while peripheral blood eNKs have significant cytotoxic advantage when combined with daratumumab.

ONCOIMMUNOLOGY (2021)

Article Multidisciplinary Sciences

Ki-67 regulates global gene expression and promotes sequential stages of carcinogenesis

Karim Mrouj, Nuria Andres-Sanchez, Geronimo Dubra, Priyanka Singh, Michal Sobecki, Dhanvantri Chahar, Emile Al Ghoul, Ana Bella Aznar, Susana Prieto, Nelly Pirot, Florence Bernex, Benoit Bordignon, Cedric Hassen-Khodja, Martin Villalba, Liliana Krasinska, Daniel Fisher

Summary: Ki-67, while not necessary for cell proliferation, plays a crucial role in tumor initiation, growth, and metastasis. Its absence leads to changes in the transcriptome and immune response, making cancer cells more susceptible to drugs and immune attacks.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Article Chemistry, Multidisciplinary

Intra-articular delivery of full-length antibodies through the use of an in situ forming depot

Alexis Fayd'herbe De Maudave, Wilhem Leconet, Karine Toupet, Michael Constantinides, Guillaume Bossis, Marion de Toledo, Jerome Vialaret, Christophe Hirtz, Adolfo Lopez-Noriega, Christian Jorgensen, Daniele Noel, Pascale Louis-Plence, Sylvestre Grizot, Martin Villalba

Summary: Monoclonal antibodies have high therapeutic potential for cancer or autoimmune diseases, but intravenous administration can lead to off-target effects. Utilizing a local controlled-delivery approach with in situ forming depot technology can help address this issue.

JOURNAL OF CONTROLLED RELEASE (2022)

Review Cell Biology

Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma

Chantal Reina-Ortiz, David Giraldos, Gemma Azaceta, Luis Palomera, Isabel Marzo, Javier Naval, Martin Villalba, Alberto Anel

Summary: NK cell-based therapies show promise as anticancer treatments. The review compares autologous and allogeneic NK cell treatments for MM and their combination with existing therapies. The placement of these treatments in clinical regimens is discussed based on patient immune profiles.

CELLS (2022)

Article Multidisciplinary Sciences

The metabolism of cells regulates their sensitivity to NK cells depending on p53 status

Sana Belkahla, Joaquin Marco Brualla, Alexis Fayd'herbe de Maudave, Paolo Falvo, Nerea Allende-Vega, Michael Constantinides, Abrar Ul Haq Khan, Lois Coenon, Catherine Alexia, Giulia Mitola, Paul Massa, Stefania Orecchioni, Francesco Bertolini, Wissem Mnif, Javier Hernandez, Alberto Anel, Martin Villalba

Summary: Leukemic cells adapt their metabolism to support their fast proliferation and can be recognized by immune cells through activating receptors. The tumor suppressor gene p53 plays a role in cell metabolism and the expression of ligands involved in immune recognition. A chemical compound called dichloroacetate (DCA) induces the expression of these ligands in tumor cells with functional p53, sensitizing them to cytotoxic lymphocytes. DCA treatment also slows down tumor growth in vivo and could potentially enhance the effectiveness of immunotherapies using CAR T cells or NK cells.

SCIENTIFIC REPORTS (2022)

Review Immunology

From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement

Lois Coenon, Martin Villalba

Summary: This review provides an overview of the latest strategies employed to improve antibody-dependent NK cell cytotoxicity, by enhancing the biological function of CD16a receptor.

FRONTIERS IN IMMUNOLOGY (2022)

Article Cell Biology

Glucose Starvation or Pyruvate Dehydrogenase Activation Induce a Broad, ERK5-Mediated, Metabolic Remodeling Leading to Fatty Acid Oxidation

Abrar Ul Haq Khan, Hamideh Salehi, Catherine Alexia, Jose M. Valdivielso, Milica Bozic, Isabel C. Lopez-Mejia, Lluis Fajas, Sabine Gerbal-Chaloin, Martine Daujat-Chavanieu, Delphine Gitenay, Martin Villalba

Summary: This study shows that glucose starvation or sustained pyruvate dehydrogenase activation can induce genetic remodeling to enhance fatty acid oxidation in cells. The signaling pathway MEK5/ERK5 plays a key role in this process, regulating lipid transport, activation of acyl-CoA synthetase long-chain family members, and induction of acyl-CoA dehydrogenases.

CELLS (2022)

Article Immunology

NK Cells Acquire CCR5 and CXCR4 by Trogocytosis in People Living with HIV-1

Dang-Nghiem Vo, Nicolas Leventoux, Mauricio Campos-Mora, Sandrine Gimenez, Pierre Corbeau, Martin Villalba

Summary: NK cells play a critical role in the antiviral immune response against HIV-1. Impaired NK cell activity is observed in HIV-1 patients, with alterations in NK cell subsets and the emergence of memory NK cells. NK cells can acquire CCR5 and CXCR4 through trogocytosis from T cells, but not CD4. HIV-1 patients exhibit distinct NK cell clusters, with increased expression of CXCR4 and CCR5 in viremic patients. Degranulation and trogocytosis may be linked in HIV-1 infection.

VACCINES (2022)

Article Pharmacology & Pharmacy

Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody

Francois Noverraz, Baptiste Robin, Solene Passemard, Benedicte Fauvel, Jessy Presumey, Emilie Rigal, Alan Cookson, Joel Chopineau, Pierre Martineau, Martin Villalba, Christian Jorgensen, Anne Aubert-Pouessel, Marie Morille, Sandrine Gerber-Lemaire

Summary: The newly developed excipient C16TreSuc can stabilize antibodies and enable pulmonary immunotherapy for the treatment of COVID-19 and other lung diseases.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2023)

Article Medicine, Research & Experimental

10th antibody industrial symposium: new developments in antibody and adoptive cell therapies

Ana Antunes, Luis Alvarez-Vallina, Federico Bertoglio, Nicolas Bouquin, Stephanie Cornen, Francis Duffieux, Pierre Ferre, Raphaelle Gillet, Christian Jorgensen, Mark B. Leick, Bernard Maillere, Helene Negre, Mireia Pelegrin, Nicolas Poirier, Dietmar Reusch, Bruno Robert, Guy Serre, Alain Vicari, Martin Villalba, Christoph Volpers, Gavin Vuddamalay, Herve Watier, Thierry Wurch, Lennart Zabeau, Stefan Zielonka, Baolin Zhang, Alain Beck, Pierre Martineau

Summary: The annual Antibody Industrial Symposium brought together scientists from academia and industry to discuss new advancements in antibody engineering and cell-based therapies. The symposium also addressed production and intellectual property protection issues.
Article Oncology

Direct Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis

Michael Constantinides, Alexis Fayd'herbe De Maudave, Marie Potier-Cartereau, Mauricio Campos-Mora, Guillaume Cartron, Martin Villalba

Summary: CD20 monoclonal antibodies have a strong ability to quickly kill B cells using different mechanisms. However, the assessment of killing is difficult. This study shows that common cytometry protocols involving centrifugation can miss important parts of the killing effect of drugs. Alternative methods are proposed to assess fast target cell killing in vitro, avoiding centrifugation or based on survival comparison or counting beads, which are applicable to B cell lines and primary tumor cells.

CANCERS (2023)

Article Biochemistry & Molecular Biology

Dynamic Changes in miRNA Expression during the Generation of Expanded and Activated NK Cells

Chantal Reina-Ortiz, M. Pilar Mozas, David Ovelleiro, Fei Gao, Martin Villalba, Alberto Anel

Summary: Therapies based on allogenic Natural Killer (NK) cells, specifically expanded and activated NK (eNK) cells, have shown significant cytotoxicity against hematological cancers. This study aims to understand the changes that occur in healthy NK cells during the expansion process in order to develop a more potent eNK-based therapy. MicroRNA (miRNA) expression analysis revealed changes in the expression of 64 miRNAs, highlighting the up-regulation of miRs-146a, -124, -34a, and -10a, which play a key role in cell survival, and the down-regulation of miRs-199a, -223, and -340, associated with increased NK cell cytotoxicity. Validation experiments confirmed the functional importance of these miRNAs and demonstrated the wide variety of changes in eNK cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Immunology

NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells

Mauricio Campos-Mora, William Jacot, Genevieve Garcin, Marie-Lise Depondt, Michael Constantinides, Catherine Alexia, Martin Villalba

Summary: NK cells infiltrate tumor environment and eliminate tumor cells. They can perform trogocytosis by acquiring tumor antigens from solid cancer cells. The extent of trogocytosis depends on the target cell and the antigen.

FRONTIERS IN IMMUNOLOGY (2023)

Article Immunology

Cytokines impact natural killer cell phenotype and functionality against glioblastoma in vitro

Minna Sivonen, Katja A. Sirvio, Sara Wojciechowski, Anssi Kailaanmaki, Satu Kaipainen, Aubrey Bailey, Martin Villalba, Tuija Kekarainen

Summary: In this study, we aimed to identify the optimal activation and expansion protocol for cytotoxic NK cells against glioblastoma in vitro. The results showed that the ex vivo proliferation capacity and functionality of NK cells were affected by multiple factors, including the donor, composition of starting material, cytokine combination, and the activation protocol. These findings could be utilized for upscaling clinical NK cell manufacturing.

FRONTIERS IN IMMUNOLOGY (2023)

Article Multidisciplinary Sciences

Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1)

Nerea Allende-Vega, Joaquin Marco Brualla, Paolo Falvo, Catherine Alexia, Michael Constantinides, Alexis Fayd'herbe de Maudave, Lois Coenon, Delphine Gitenay, Giulia Mitola, Paul Massa, Stefania Orecchioni, Francesco Bertolini, Isabel Marzo, Alberto Anel, Martin Villalba

Summary: Solid tumor cells have altered metabolism that can protect them from cytotoxic lymphocytes, but metformin can increase tumor cell sensitivity to cytotoxic lymphocytes. Research shows that metformin induces expression of NKG2DL and ICAM-1, promoting binding between lymphocytes and tumor cells, and reducing the growth of human hematological tumor cells.

SCIENTIFIC REPORTS (2022)

No Data Available